Letters to the Editor
13 September 2022
Vol. 74 No. 2 (2022)
Patients with systemic lupus erythematosus and their experience with vaccination against COVID-19: a descriptive and explanatory study
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
1083
Views
493
Downloads
Authors
Not available
Altmetrics
Downloads
Download data is not yet available.
Citations
Ceccarelli F, Covelli V, Olivieri G, et al. Systemic lupus erythematosus before and after COVID-19 lockdown: how the perception of disease changes through the lenses of narrative medicine. Healthc. 2021; 9: 726. DOI: https://doi.org/10.3390/healthcare9060726
Priori R, Pellegrino G, Colafrancesco S, et al. SARS-CoV-2 vaccine hesitancy among patients with rheumatic and musculoskeletal diseases: a message for rheumatologists. Ann Rheum Dis. 2021; 80: 953-4. DOI: https://doi.org/10.1136/annrheumdis-2021-220059
Watson, Clark, & Tellegen, 1988. Italian Version Terracciano, McCrae & Costa, 2003.
Wilson RS, Zwickle A, Walpole H. Developing a broadly applicable measure of risk perception. Risk Anal. 2019; 39: 777-91. DOI: https://doi.org/10.1111/risa.13207
How to Cite
Patients with systemic lupus erythematosus and their experience with vaccination against COVID-19: a descriptive and explanatory study. (2022). Reumatismo, 74(2). https://doi.org/10.4081/reumatismo.2022.1491
Copyright (c) 2022 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
